Skip to content

Pan Tumor Rollover Study

Cancer

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Signed Written Informed Consent.
* Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study.
* On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study.
* WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF.

Exclusion Criteria:

* Participant is not eligible for study treatment per the Parent Study eligibility criteria.
* Participants not receiving clinical benefit as assessed by the Investigator.
* Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant.
* Other protocol-defined Inclusion/Exclusion Criteria apply

Study Location

Local Institution
Local Institution
Vancouver, British Columbia
Canada

Contact Study Team

Local Institution - 0040
Local Institution - 0040
Montreal, Quebec
Canada

Contact Study Team

Local Institution - 0111
Local Institution - 0111
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Site 0111

Princess Margaret Cancer Centre
Princess Margaret Cancer Centre
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Marcus Butler, Site 0280

4169464628
Local Institution - 0308
Local Institution - 0308
Montreal, Quebec
Canada

Contact Study Team

Primary Contact

Site 0308

Local Institution
Local Institution
Halifax, Nova Scotia
Canada

Contact Study Team

Local Institution - 0168
Local Institution - 0168
Oshawa, Ontario
Canada

Contact Study Team

Study Sponsored By
Bristol-Myers Squibb
Participants Required
More Information
Study ID: NCT03899155